SUNNYVALE, Calif., July 12 /PRNewswire-FirstCall/ --
Scios Inc. (Nasdaq: SCIO), today announced that the company will report
second-quarter financial results and provide an updated 2002 outlook on
Thursday, July 25, 2002. The announcement will be followed by the Scios
Investor Day with the investment community from 10:00 a.m. to 12.30 p.m. EDT.
Richard B. Brewer, president and chief executive officer, and other
members of the Scios senior management team will discuss the company's
progress with its lead product, Natrecor(R) (nesiritide) and its new product
pipeline. A panel of heart failure experts also will discuss current
treatment practices.
To access the Scios Investor Day via webcast, participants should go to
the company's website at http://www.sciosinc.com. To access the conference call,
participants calling from the U.S. or Canada should dial 800-364-4174 or
800-399-7909. International callers can dial 706-634-5159. All conference
call participants should request Conference I.D. 4381069.
Scios Inc.
Scios is a biopharmaceutical company that discovered, developed and
markets Natrecor(R), the first new treatment for acutely decompensated
congestive heart failure in more than a decade. Scios has a growing pipeline,
including SCIO-469, one of the first oral p38 kinase inhibitors in clinical
trials. The Company's disease-based technology platform integrates expertise
in protein biology with computational and medicinal chemistry to identify
novel targets and rationally design small molecule compounds for large markets
with unmet medical needs.
Forward Looking Safe Harbor Disclaimer
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. We generally identify such forward-looking statements
using words like "believe," "intend," "expect," "may," "should," "plan,"
"project," "contemplate," "anticipate" or similar statements. Statements that
are not historical facts are forward-looking statements based on current
assumptions that involve risks and uncertainties. These risks and
uncertainties may include the sales penetration and success of Natrecor, the
success of clinical trials of Natrecor and our pipeline products, including
SCIO-469, as well as other risks detailed from time to time in the reports
filed by Scios with the SEC, including the Company's quarterly reports and
annual report on Form 10-K. Actual results, performance or achievements of
Scios may differ significantly from those described in these forward-looking
statements. Scios disclaims any intention or obligation to update or revise
any financial projections or forward-looking statements, whether as a result
of new information, future events or otherwise.
SOURCE Scios, Inc.
 back to top
Related links:
http://www.sciosinc.com
CONTACT:
media and investors, Suzanne Beveridge of
Scios Inc., +1-408-616-8328; or media, Jim Weiss of WeissCom
Partners, +1-415-260-1274; or investors, Fern Lazar of Lazar
Partners, +1-212-867-1765, for Scios, Inc.
|
